Anna Offersgaard

Ms. Anna Offersgaard

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Science Advances
Verified
Journal Article
Open access
YZYuyong Zhou
Yuyong Zhou
KGKaren Anbro Gammeltoft
Karen Anbro Gammeltoft
LRLine Abildgaard Ryberg
Line Abildgaard Ryberg
LPLong V. Pham
Long V. Pham
HTHelena Damtoft Tjørnelund
Helena Damtoft Tjørnelund
JGJudith Gottwein
Judith Gottwein
The oral protease inhibitor nirmatrelvir is of key importance for prevention of severe coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) escape from nirmatrelvir in cell culture. Resistant variants harbored combinations of substitutions in the SARS-CoV-2 main protease (Mpro). Reverse genetics revealed that E166V and L50F + E166V conferred high resistance in infectious culture, replicon, and Mpro systems. While L50F, E166V, and L50F + E166V decreased replication and Mpro activity, L50F and L50F + E166V variants had high fitness in the infectious system. Naturally occurring L50F compensated for fitness cost of E166V and promoted viral escape. Molecular dynamics simulations revealed that E166V and L50F + E166V weakened nirmatrelvir-Mpro binding. Polymerase inhibitor remdesivir and monoclonal antibody bebtelovimab retained activity against nirmatrelvir-resistant variants, and combination with nirmatrelvir enhanced treatment efficacy compared to individual compounds. These findings have implications for monitoring and ensuring treatments with efficacy against SARS-CoV-2 and emerging sarbecoviruses.

5 July 2023 in Nature
Verified
Journal Article
Closed access
PDF file
ASAnna V. Sherwood
Anna V. Sherwood
LRLizandro R. Rivera-Rangel
Lizandro R. Rivera-Rangel
LRLine A. Ryberg
Line A. Ryberg
HLHelena S. Larsen
Helena S. Larsen
KAKlara M. Anker
Klara M. Anker
JVJeppe Vinther
Jeppe Vinther

15 October 2021 in Viruses
Verified
Journal Article
Open access
PDF file
YZYuyong Zhou
Yuyong Zhou
KGKaren Anbro Gammeltoft
Karen Anbro Gammeltoft
AGAndrea Galli
Andrea Galli
AOAnna Offersgaard
Anna Offersgaard
UFUlrik Fahnøe
Ulrik Fahnøe
JGJudith Gottwein
Judith Gottwein
We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In VeroE6 cells, rimantadine was most potent followed by memantine and amantadine (50% effective concentrations: 36, 80 and 116 µM, respectively). Rimantadine also showed the highest selectivity index, followed by amantadine and memantine (17.3, 12.2 and 7.6, respectively). Similar results were observed in human hepatoma Huh7.5 and lung carcinoma A549-hACE2 cells. Inhibitors interacted in a similar antagonistic manner with remdesivir and had a similar barrier to viral escape. Rimantadine acted mainly at the viral post-entry level and partially at the viral entry level. Based on these results, rimantadine showed the most promise for treatment of SARS-CoV-2.

1 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KLKeven Lothert
Keven Lothert
AOAnna Offersgaard
Anna Offersgaard
APAnne F. Pihl
Anne F. Pihl
CMChristian K. Mathiesen
Christian K. Mathiesen
TJTanja B. Jensen
Tanja B. Jensen
Michael Werner WolffMichael Werner Wolff
Michael Werner Wolff
There is a large unmet need for a prophylactic hepatitis C virus (HCV) vaccine to control the ongoing epidemic with this deadly pathogen. Many antiviral vaccines employ whole viruses as antigens. For HCV, this approach became feasible following the development of infectious cell culture systems for virus production. However, the lack of efficient downstream processes (DSP) for HCV purification poses a roadblock for the development of a whole virus vaccine. Using cell culture-derived genotype 1a HCV we developed a scalable and efficient DSP train, employing commonly used clarification and ultrafiltration techniques, followed by two membrane-based chromatography steps. For virus capture, steric exclusion chromatography using cellulose membranes was established, resulting in a virtually complete virus recovery with > 99% protein and 84% DNA depletion. Virus polishing was achieved by sulphated cellulose membrane adsorbers with ~ 50% virus recovery and > 99% protein and 90% DNA depletion. Additional nuclease digestion resulted in 99% overall DNA depletion with final DNA concentrations of 2 ng/mL. Process results were comparable for cell culture-derived HCV of another major genotype (5a). This study provides proof-of-concept for establishment of an efficient and economically attractive DSP with potential application for production of an inactivated whole virus vaccine against HCV for human use.

29 June 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
AOAnna Offersgaard
Anna Offersgaard
CHCarlos Rene Duarte Hernandez
Carlos Rene Duarte Hernandez
APAnne Finne Pihl
Anne Finne Pihl
RCRui Costa
Rui Costa
NVNandini Prabhakar Venkatesan
Nandini Prabhakar Venkatesan
JGJudith Gottwein
Judith Gottwein
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. This study aimed to establish SARS-CoV-2 production in the scalable packed-bed CelCradleTM 500-AP bioreactor. CelCradleTM 500-AP bottles with 0.5 L working volume and 5.5 g BioNOC™ II carriers were seeded with 1.5 × 108 Vero (WHO) cells, approved for vaccine production, in animal component-free medium and infected at a multiplicity of infection of 0.006 at a total cell number of 2.2–2.5 × 109 cells/bottle seven days post cell seeding. Among several tested conditions, two harvests per day and a virus production temperature of 33 °C resulted in the highest virus yield with a peak SARS-CoV-2 infectivity titer of 7.3 log10 50% tissue culture infectious dose (TCID50)/mL at 72 h post-infection. Six harvests had titers of ≥6.5 log10 TCID50/mL, and a total of 10.5 log10 TCID50 were produced in ~5 L. While trypsin was reported to enhance virus spread in cell culture, addition of 0.5% recombinant trypsin after infection did not improve virus yields. Overall, we demonstrated successful animal component-free production of SARS-CoV-2 in well-characterized Vero (WHO) cells in a scalable packed-bed bioreactor.

21 September 2023 in Viruses
Verified
Journal Article
Open access
PDF file
KGKaren Anbro Gammeltoft
Karen Anbro Gammeltoft
YZYuyong Zhou
Yuyong Zhou
LRLine Abildgaard Ryberg
Line Abildgaard Ryberg
LPLONG VAN PHAM
LONG VAN PHAM
ABAlekxander Binderup
Alekxander Binderup
JGJudith Gottwein
Judith Gottwein
Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the future efficacy of such direct-acting antivirals. To gain knowledge on viral correlates of resistance to Mpro inhibitors, we selected resistant SARS-CoV-2 under treatment with the nirmatrelvir-related protease inhibitor boceprevir. SARS-CoV-2 selected during five escape experiments in VeroE6 cells showed cross-resistance to nirmatrelvir with up to 7.3-fold increased half-maximal effective concentration compared to original SARS-CoV-2, determined in concentration–response experiments. Sequence analysis revealed that escape viruses harbored Mpro substitutions L50F and A173V. For reverse genetic studies, these substitutions were introduced into a cell-culture-infectious SARS-CoV-2 clone. Infectivity titration and analysis of genetic stability of cell-culture-derived engineered SARS-CoV-2 mutants showed that L50F rescued the fitness cost conferred by A173V. In the concentration–response experiments, A173V was the main driver of resistance to boceprevir and nirmatrelvir. Structural analysis of Mpro suggested that A173V can cause resistance by making boceprevir and nirmatrelvir binding less favorable. This study contributes to a comprehensive overview of the resistance profile of the first-in-line COVID-19 treatment nirmatrelvir and can thus inform population monitoring and contribute to pandemic preparedness.